• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir

tetano

Editor, Senior Moderator
J Toxicol Sci. 2018;43(8):507-512. doi: 10.2131/jts.43.507.
[h=1]Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir.[/h] Lubna NJ[SUP]1[/SUP], Nakamura Y[SUP]2[/SUP], Hagiwara-Nagasawa M[SUP]2[/SUP], Goto A[SUP]1[/SUP], Chiba K[SUP]1[/SUP], Kitta K[SUP]3[/SUP], Izumi-Nakaseko H[SUP]1,[/SUP][SUP]2[/SUP], Ando K[SUP]1,[/SUP][SUP]2[/SUP], Naito AT[SUP]1,[/SUP][SUP]2[/SUP], Akie Y[SUP]3[/SUP], Sugiyama A[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] We analyzed electropharmacological characteristics of microminipigs under halothane-anesthesia using anti-influenza virus drug oseltamivir, which has been known to possess multi-channel blocking properties, including Na[SUP]+[/SUP], Ca[SUP]2+[/SUP] and K[SUP]+[/SUP] channels (n = 4). Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 ?g/mL, respectively. The low dose did not alter any of the cardiovascular variables. The middle dose decreased the heart rate at 30 min after the start of the infusion. The high dose transiently returned the heart rate toward the baseline for 10-15 min, but decreased it for 20-60 min; decreased the mean blood pressure for 5-60 min; prolonged the PR interval for 10-60 min, and the QRS width for 10-20 min; but shortened the QT interval for 10-30 min, and the QTc for 5-60 min. Thus, oseltamivir can suppress the sinus automaticity, and atrioventricular nodal and intraventricular conduction; and decrease the mean blood pressure, extents of which were greater in microminipigs than in beagle dogs in our previous observation in spite of similar plasma concentrations, reflecting higher sensitivity of microminipigs for Na[SUP]+[/SUP] and Ca[SUP]2+[/SUP] channel inhibition than that of beagle dogs. In contrast to beagle dogs, oseltamivir shortened the repolarization period in microminipigs, indicating that oseltamivir can more potently inhibit the inward currents than the outward ones in the hearts of microminipigs. This information may help improve utilizatione of microminipigs as a laboratory animal.


[h=4]KEYWORDS:[/h] Halothane; Microminipig; Oseltamivir; Safety pharmacology; Short QT

PMID: 30078836 DOI: 10.2131/jts.43.507
 
Back
Top Bottom